Solitary pulmonary nodules (SPNs) are common incidental findings in patients undergoing thoracic imaging studies. An SPN is a rounded opacity, circumscribed or poorly defined, measuring up to 3 cm in diameter. The radiologic characteristics, medical history, and physical examination results are helpful for distinguishing between benign and malignant SPNs. An estimated 150,000 SPNs are identified at chest radiography each year, making it important for physicians to understand how to characterize them and evaluate patients for potential malignancy. A number of features visible at thoracic computed tomography (CT) are useful for determining whether an SPN is benign or malignant. 2-18 F-fluoro-2-deoxy-D-glucose positron emission tomography-CT (PET/CT) plays an important role in the diagnosis and management of lung cancer and is an increasingly valuable tool for the characterization and management of SPNs. Unlike CT and magnetic resonance imaging, PET provides information regarding the metabolic activity of a nodule. The information provided by PET/CT imaging allows for both morphologic and anatomic characteristics and physiological data in the form of metabolism within the nodule itself. The information gained from PET is extremely useful for directing patient management and may obviate the need for invasive diagnostic procedures.
THE SOLITARY PULMONARY NODULE
Solitary pulmonary nodules (SPNs) represent a diverse range of benign and malignant lesions ( Table 1 ). The Fleischner Society 1 defines an SPN as a rounded opacity, circumscribed or poorly defined, measuring up to 3 cm in diameter, completely surrounded by lung. In the most restrictive definition, SPNs are unassociated with atelectasis, hilar enlargement, or pleural effusion. 2, 3 Opacities larger than 3 cm in diameter are referred to as masses to reflect to high rate of malignancy with lesions of this size. 2, 4 
SPN DEMOGRAPHICS
The prevalence of SPNs at chest radiography has been estimated at 1 in 500 chest radiographs. 2, 3 Nodules are even more commonly detected at thoracic computed tomography (CT), and the problem of the incidental detection of pulmonary nodule is increasing due to the higher sensitivity of thoracic CT compared with chest radiography, and the increasing utilization of thoracic CT. 5 It is critically important for physicians to have a firm understanding of how to integrate clinical, laboratory, and imaging data to develop an appropriate approach to the management of an SPN. 3 
CLINICAL CHARACTERISTICS IMPACTING THE LIKELIHOOD OF MALIGNANCY WITHIN AN SPN
A number of clinical factors impact the likelihood of malignancy within an SPN, but the most important of these are the patient's age, history of smoking, and history of earlier malignancy. 2 
Patient Age
As a patient's age increases, the risk for malignancy within an SPN increases. Multiple studies examining the correlation between age and malignancy have found that the risk for malignancy within an SPN is approximately double for patients older than the age of 50 years compared with patients younger than the age of 50 years. 6 Unfortunately, it is difficult 
Malignant Benign
to identify an age below which primary pulmonary malignancy need not be considered within the differential diagnosis of SPNs discovered at chest radiography. Some of this difficulty arises from the fact that a history of smoking strongly impacts the likelihood of malignancy within an SPN (see below). Furthermore, certain conditions that preferentially affect younger patients-such as tracheobronchial papillomatosis (Fig. 1 )-may increase the likelihood of malignancy within an SPN. Finally, uncommon primary pulmonary malignancies typically affect patients at a younger age than bronchogenic carcinoma-such malignancies include carcinoid tumors and pulmonary blastomas. Nevertheless, the prevalence of malignancy within an SPN in a nonsmoking patient without a history of malignancy, under the age of 35 years, is <1%. 7 This prevalence of malignancy is low enough that most SPNs in such patients may be approached under the assumption that primary pulmonary malignancy is a very unlikely cause for the nodule.
Smoking History
Cigarette smoking is the most important causative factor in the development of bronchogenic malignancies, and therefore strongly influences the likelihood of malignancy in SPNs. 8 The risk of the development of bronchogenic carcinoma increases with the quantity of cigarette consumption and the duration of smoking, 8 but the lack of a smoking history does not guarantee that an SPN does not harbor malignancy. Other risk factors for bronchogenic carcinoma, which will increase the likelihood of malignancy in an SPN, include occupational or environmental exposures such as asbestos and radon, certain metals (cadmium, chromium, and arsenic), radiation, some organic chemicals, and pulmonary scars.
History of Extrapulmonary Malignancy
In an adult patient with a history of earlier malignancy who presents with a new lung nodule at imaging, the physician must consider the possibility that the new nodule represents a primary bronchogenic malignancy, a solitary metastases ( Fig. 2) , or a benign finding. The frequency of each of these etiologies varies with the age of the patient, smoking history, and the type of study (surgical vs. population series). In a study of more than 800 patients with known cancer over a period of 35 years, Cahan et al 9 found that at least 63% of SPNs (500 of more than 800 patients) were due to primary lung malignancy, at least 25% (196 of more than 800 patients) of SPNs were the result of solitary metastases, and in only 11 of more than 800 patients (1.4%) were the SPNs the result of benign lesions. The distribution of malignant versus benign lesions in this study, 9 and other surgical studies, differs from data reported in population studies and reflects the bias intrinsic to studies based on surgical patient cohorts.
Of particular importance is the histopathology of the extrapulmonary malignancy. In a study of 149 adult patients with synchronous or metachronous extrapulmonary neoplasms and noncalcified SPNs 5 to 30 mm in size found at thoracic CT, 10 the nodules in patients with primary carcinomas of the head/neck, bladder, esophagus, bile ducts, ovary, prostate, breast, cervix, and stomach were more likely to be the result of a new primary lung malignancy than pulmonary metastases. In contrast, the SPNs of patients with primary testicular carcinoma, melanoma, or sarcomas ( Fig. 2 ) are far more likely to harbor metastatic disease than bronchogenic carcinomas. 10 No patient under the age of 44 years had bronchogenic malignancy in this study, and 30 of 149 patients (20%) in this cohort had benign SPNs. 10 The study of Cahan et al 9 showed a 
similar SPN etiology dependence on the histopathology of the extrapulmonary lesion.
When accounting for numerous factors impacting the likelihood of malignancy in a nodule, it has been estimated that the probability of malignancy in an SPN in an adult patient discovered at chest radiography is approximately 40%. 11 The task of the physician caring for patients with SPNs is to use clinical, laboratory, and imaging information to modify this probability to a sufficiently low likelihood that the lesion may be safely followed or to a sufficiently high likelihood that intervention is warranted.
CHEST RADIOGRAPHIC AND THORACIC CT FEATURES OF MALIGNANT AND BENIGN SPNs

Likelihood Ratios
A number of morphologic features of SPNs visible at chest radiography and thoracic CT influence the likelihood that an SPN is benign or malignant ( Table 2 ). These features have variable predictive value. The process by which these features are integrated into an overall assessment of the likelihood of malignancy is referred to as Bayesian analysis, and this process underlies the core of SPN management.
The ability of clinical, laboratory, and imaging features to impact the likelihood of a benign or malignant SPN diagnosis is often quantified in terms of likelihood ratios (LRs); LRs for individual imaging features of SPNs have been published. 7, 12 The LRs for various clinical factors, along with imaging features of SPNs, can be combined to provide an overall assessment of the likelihood of malignancy for a given SPN. 2 For example, the LR for an upper lobe location for an SPN has been reported as 1.22 in 1 publication 7 -this value indicates a slightly increased likelihood of malignancy when an SPN is found in the upper lobes as opposed to other locations. Using the previously asserted baseline prevalence of malignancy within an SPN discovered at chest radiography of 40%, the prevalence of malignancy for an upper lobe SPN increases slightly to 49%. In contrast, the LR for lack of significant tracer utilization at 2-18 F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) is 0.06. 12 In this example, an SPN discovered at chest radiography subsequently shown to possess no significant metabolic activity at FDG PET will have a probability of carcinoma of only 2.4%.
Web-based calculators (www.chestx-ray.com) are available to automate the use of LRs in determining the probability of carcinoma in an SPN. Users simply input the information regarding certain clinical factors, such as age and smoking history, and several relevant radiologic features of the SPN, and a likelihood of malignancy within the SPN is instantaneously calculated.
Some of the SPN morphologies visible on chest radiography and thoracic CT that have the greatest utility for predicting a benign or malignant etiology for an SPN are reviewed below. The role of FDG PET in the evaluation of the SPN has grown enormously in recent years and FDG PET has been proven to be a very powerful tool for nodule evaluation. Therefore, FDG PET is discussed separately in detail subsequently.
THORACIC IMAGING FEATURES THAT PREDICT A MALIGNANT SPN ETIOLOGY
A host of imaging features has been evaluated for their ability to suggest whether or not an SPN found at chest radiography or thoracic CT is malignant ( Table 2 ). Some of the more important predictors of malignancy within an SPN include the appearance of the edge (margin or contour) of the nodule, the shape of the nodule, nodule size, nodule attenuation at thoracic CT, and hypermetabolism at FDG PET.
Nodule Edge/Margin/Contour
The edges (also often referred to as the margin, border, or contour) of a nodule describe the interface of the nodule with adjacent lung, and may be characterized as circumscribed (smooth), lobulated, spiculated, or irregular. A smooth, or circumscribed, nodule margin is present when the nodule edges are easily traced and the interface with adjacent lung is sharply demarcated (Fig. 3A) . Circumscribed nodule margins are typical of benign lesions and are uncommonly present with primary lung malignancies. However, the predictive value of a smooth nodule margin is lowered by the fact that metastatic pulmonary nodules often present in this manner. A nodule is described as lobulated when an undulating contour is present ( Fig. 3B )-this nodule morphology is commonly seen with malignancy, although benign lesions may occasionally present in this manner. A nodule is described as having a spiculated border when irregular, linear "spike-like" points radiate from the nodule into the surrounding lung parenchyma ( Fig. 3C ). Unlike circumscribed nodule borders, the edges of a spiculated nodule are not easily traced. A spiculated nodule edge is a strong predictor of malignancy and is a common manifestation of bronchogenic carcinoma ( Fig. 3C, Fig. 4 ). 2 The margin of a nodule may be described as irregular when the interface the nodule creates with the lung is not properly described as circumscribed, lobulated, or spiculated. 
Nodule Shape
Nodule shapes may be described as round, oval, notched, or irregular. The nodule shape descriptors round and oval carry little predictive value as both benign and malignant SPNs may present with these shapes. The notched shape, however, is a fairly strong predictor of malignancy within an SPN. The notched nodule shape refers to a concavity within an otherwise generally spherical nodule, usually associated with a bronchus or blood vessel entering the nodule at or near the site of the concavity (Fig. 3B ). This shape is fairly similar to the "lobulated" nodule border characteristic, and both descriptors imply a similar pathophysiological process-differential growth of a nodule, which is typical of malignancy. Pulmonary malignancies, particularly bronchogenic carcinomas, grow in an asymmetric manner, which results in variable convexities and concavities along the surface of a nodule, outwardly manifesting as a lobulated edge or notched shape.
Nodule Size
As a general rule, the rate of malignancy within a nodule rises as nodule size increases. 2 Unfortunately, there is no lower size limit at which malignancy can be confidently excluded. In the study by Ginsberg et al, 13 among 254 patients who underwent video-assisted thoracoscopic resection of a single pulmonary nodule, 114 nodules were benign and 140 were malignant. In this study, a total of 685 nodules were resected and 36% of these nodules measuring <1 cm were malignant. Nodules >1 cm but <3 cm were more likely to be malignant than nodules <1 cm, but there is no "safe limit" below which malignancy can be excluded within a pulmonary nodule, particularly in patients with current or previous malignancy. There is certainly a trend, which favors a benign diagnosis for smaller nodules, but nodule size alone is an insufficiently sensitive discriminator between benign and malignant nodules ( Fig. 5 ).
Nodule Attenuation at Thoracic CT
The density, or attenuation, of a nodule at CT has been correlated with the presence of certain types of primary pulmonary malignancies, particularly bronchioloalveolar carcinoma (BAC). It has been noted that pure ground-glass opacity nodules (often referred to as subsolid nodules-nodules in which the underlying pulmonary architecture is visible through the lesion) correlate histopathologically with the replacement growth pattern typical of BAC (Figs. 6, 7). When ground-glass opacity nodules begin to show solid components, increasingly advanced histopathologic features of malignancy are often present (Fig. 6B ). The ground-glass opacity appearance of a focal nodule at thoracic CT is not completely specific for BAC as areas of focal fibrosis and atypical adenomatous hyperplasia may present in this manner. 14 A number of other morphologic features of SPNs occasionally visible at chest radiography and usually readily appreciable with CT have been associated with malignancy ( Table 2 ). Some of these features include the presence of an air bronchogram within an SPN ( Fig. 8A ) and the presence of nonenlarged vessels entering an SPN (the "convergence" sign Fig. 8B ) among others. 
THORACIC IMAGING FEATURES THAT PREDICT A BENIGN SPN ETIOLOGY
Certain morphologic features of an SPN found at chest radiography or thoracic CT are associated with benign diagnoses. These features include the feeding artery and draining vein of an arteriovenous malformation (Figs. 9, 10), rounded atelectasis ( Fig. 11 ), mucous plugging ( Fig. 12 ), certain patterns of calcification within a nodule, visible fat within a nodule, lack of nodule enhancement at thoracic CT or magnetic resonance imaging (MRI), nodule growth character-istics, and lack of significant tracer utilization at FDG PET. The more important and commonly encountered morphologic features that allow an SPN discovered at thoracic imaging to be diagnosed as benign will be reviewed below.
Patterns of Calcification Within an SPN
Calcification within an SPN generally indicates that an SPN is benign, and typically occurs within nodules resulting from granulomatous infections or hamartomas. The mere presence of calcium within an SPN is a fairly strong indicator 15 This study, and the study of subsequent investigators, has repeatedly shown that the presence of calcification within a nodule predicts that the SPN is benign, but does not absolutely exclude malignancy. Calcification within bronchogenic malignancies is typically rarely visible at chest radiography ( Fig. 13A ), but can occasionally be appreciated with thoracic CT (Fig. 13B ). Metastatic lung nodules ( Fig. 14) may also calcify, particularly in patients with thyroid carcinoma, osteosarcoma, chrondrosarcoma, and mucinous tumors, such as some ovarian malignancies. Ultimately the pattern of calcification within an SPN is more useful than the mere presence of calcification within an SPN for determining if a lesion is benign. Indeed, the pattern of calcification, rather than the mere presence or absence, is 1 of the 2 primary noninvasive criteria, which allow an SPN to be considered absolutely benign (the other is lack of growth over a period of time; see below). 2 Four benign patterns of SPN calcification are recognized: diffuse calcification, central calcification, laminar ("target") calcification, and chondroid ("popcorn") calcification (Figs. 15-17 and 18C). 2 When calcification occurs within a malignant primary pulmonary neoplasm, the calcification is often stippled (tiny, punctuate foci of calcium) or eccentric. The latter pattern is thought to result from a malignant nodule arising adjacent to and engulfing a calcified granuloma.
Assessing an SPN for calcification is a powerful means to determine whether or not further evaluation is required for a nodule. Nevertheless, a few caveats must be borne in mind: 1. When attempting to discern the pattern of SPN calcification, if a significant soft tissue component is present, caution is warranted ( Fig. 13B ). How much noncalcified soft tissue is "allowable" to still consider a nodule as benign is debatable, but the more visible the noncalcified component, the more the nodule should be regarded as indeterminate 2. Calcification patterns within nodule are not reliable for distinguishing between benign and malignant nodules when patients have extrapulmonary malignancies that are known to calcify or ossify ( Fig. 14) and 3. Care should be taken when considering a nodule calcified at chest radiography.
Regarding the latter, Berger et al 16 evaluated the ability of 14 board-certified radiologists to determine whether or not an SPN was calcified at chest radiography and found that the positive predictive value for a "definitely calcified" assessment of a nodule was 93%. As nodules considered calcified at chest radiography generally are not evaluated further, the implication of this study is that nearly 7% of patients with noncalcified SPNs could be incorrectly classified as calcified at chest radiography and inappropriately dismissed without further evaluation. Recalling the baseline prevalence of malignancy in an SPN of 40% discussed previously, it is therefore conceivable that 3% to 4% of malignant SPNs discovered at chest radiography could be incorrectly dismissed as calcified and therefore benign.
There are few guidelines for determining whether or not a nodule is calcified. One useful criterion, however, is nodule size: the smaller the nodule, the more likely it is calcified. This relationship exists because smaller nodules require sufficient density to achieve the level of contrast resolution needed to allow them to be visible at chest radiography. Nodules containing calcium are intrinsically denser than noncalcified nodules; therefore, for a small nodule to be visible at chest radiography, it likely contains calcium. In a study evaluating this concept, Ketai et al 17 found that nodules <7 mm in diameter at chest radiography were very likely to be calcified, particularly if the nodule appeared to be as dense as or denser than the adjacent rib ( Fig. 16A ). These data correlate fairly well with the notion that primary bronchogenic carcinomas, which are typically noncalcified, are not visible on chest radiographs when <1 cm in size. 2, 17, 18 Fat Within a Nodule: Hamartoma
Hamartomas are mesenchymal lesions that contain variable degrees of connective tissue elements, such as smooth muscle, myxomatous tissue, epithelial tissue, adipose tissue, fibrous tissue, and cartilage. Hamartoma is one of the more common causes of an SPN and more than 90% of hamartomas present as a peripheral SPN. Hamartomas present as round, circumscribed, or mildly lobulated lesions that range from 1 to 4 cm in diameter, but occasionally may be much larger ( Fig. 18 ).
Hamartomas may manifest as a nonspecific SPN, but calcification may occur in 5% to 50% of lesions on CT. 19 Occasionally the pattern of calcification within a hamartoma will reflect the presence of cartilage within the lesion-socalled "popcorn," or chondroid, calcification (Figs. 17B, 18C). Hamartomas may also contain adipose tissue and may show macroscopic evidence of fat at CT, allowing a specific diagnosis (Figs. 18A, B ). 19 Nodule Enhancement at Thoracic CT or MRI Pulmonary malignancies are vascularized lesions that typically show contrast enhancement at enhanced thoracic CT or MRI examinations. Although the sensitivity of contrast enhancement at thoracic CT for the detection of malignancy is as high as 98%, 2,20 the specificity for this finding is only 58% because benign nodules, such as active granulomas rounded atelectasis, focal pneumonia, and hamartomas, may enhance after contrast administration. Although the presence of contrast enhancement does not reliably discriminate between benign and malignant lesions, the lack of contrast enhancement at thoracic CT or MRI is a strong indicator that a pulmonary nodule is benign. In a multicenter study, Swensen et al 20 showed when using a specific contrast-enhanced thoracic CT protocol, that nodule enhancement of r15 HU carries a negative predictive value of 96% for malignancy.
Nodule Growth Characteristics
Malignant pulmonary nodules will show growth on serial imaging studies, although the rate of growth may vary widely depending on the type of malignancy. The detection of growth within a nodule is one of the main reasons comparison chest radiographs are of paramount importance when assessing nodules-every effort should always be made to obtain earlier radiographs for this purpose. 2 The presence of growth is often taken as an indicator of the potential for malignancy within an SPN, and thus the demonstration of growth serves as an endpoint for nodule surveillance with chest radiography or thoracic CT. Similarly lack of growth is often used as an indicator that a pulmonary nodule is benign-clear demonstration that a nodule has shown no growth for a period of 2 years or more has traditionally been considered an absolute indicator that the lesion is benign. 2 This criterion for a benign nodule has been questioned in recent years on the basis that the original data supporting this approach are insufficient. 2, 21 Nevertheless, 2-year nodule stability at imaging is still widely regarded as an absolute indication that a nodule is benign, 2, 7, 16, 19 but with several caveats: 1. To determine if a nodule is truly stable, it must be reasonably well seen. This statement does not indicate that only CT is sufficient for determining nodule stability, although one of the many advantages of thoracic CT for nodule assessment is that the margins of a nodule are far better appreciated with CT than chest radiography in many patients FIGURE 11 . Rounded atelectasis: chest radiography and thoracic computed tomography (CT). Frontal (A) and lateral (B) chest radiographs show volume loss and pleural abnormality in the left thorax, with an oblong nodule (arrow) in the left lung. Although these findings raise the possibility of rounded atelectasis, they are insufficiently specific to exclude malignancy. Thoracic CT displayed in lung (C) and soft tissue (D) windows shows the left lung opacity is associated with vessels (double arrowheads) spiraling into the lesion (arrow), representing the "comet tail" sign. Volume loss (note posterior displacement of left major fissure, just anterior to arrowheads in C) is also present. The lesion (arrow) obeys other features expected with rounded atelectasis, such as a homogenous appearance and contact with abnormal pleura (single arrowhead in D). 2. Accurate determination of growth of small nodules (<1 cm) on thoracic CT can be difficult. In particular, caution regarding confident assessments of lack of growth for small nodules is warranted. Automated software calculation of nodule volume may provide an improved approach to the assessment of such small nodules 7,19 ( Fig. 19 ) and
3. Ground-glass opacity nodules detected at thoracic CT may reflect slow-growing neoplasms, such as BAC (Figs. 6, 7). Therefore, some investigators have advocated that such nodules show no growth for at least 5 years before dismissing them as benign. 2, 14 In recent years, further refinements in software now allow automated calculation of the volume of a nodule at serial thoracic CT examinations ( Fig. 19 ). Preliminary studies suggest that the use of such software provides a more robust determination of nodule size, with less interobserver variability among serial CT examinations when assessing for nodule growth compared with manual measurements. 7, 19 When an SPN is detected at chest radiography or thoracic CT and earlier imaging studies are available, determination of the nodule growth rate can provide an indication regarding the nodule's malignant potential. To make this determination, the nodules' doubling time can be calculated. The doubling time of a nodule is the time required for the nodule to double in volume, not diameter, and is governed by the formula for the volume of a sphere-4/3pr 3 . An increase in the diameter of a nodule by 26% reflects a doubling of the volume of a nodule; when a nodule has doubled in diameter, its volume has increased 8-fold. In general, pulmonary malignancies (Figs. 5 and 20) will double in volume between 30 and 480 days. Lesions that grow faster than a doubling time of 30 days are often infectious in nature, and doubling times longer than 480 days are also more typical of benign lesions. However, there are exceptions to these rules. Rarely some cancers, particularly small cell carcinomas, may double in volume in <30 days. On the other end of the spectrum, some pulmonary malignancies, particularly BACs, may grow very slowly (Fig. 7) ; doubling times as long as 1486 days have been noted. In Figure 7 , the small BAC grew from 4 mm to 9 mm over a period of 1827 days, yielding a doubling time of 521 days. For this reason, slow doubling times cannot be regarded as an absolute indicator of a benign nodule.
PET AND PET/CT TECHNOLOGY
PET has a well established role in the diagnosis and management of lung malignancy. Unlike anatomic imaging methods, which rely on assessment of the morphologic characteristics of pulmonary opacities, PET imaging with radioactive tracers allows for the identification of metabolic activity within the lesion to indicate its aggressive potential. PET imaging exploits the detection of photons created as a result of the annihilation of a positively charged electron (positron) colliding with a nearby negatively charged electron, which produces two 511 keV photons emitted in near opposite directions. Photons that interact with the sophisticated crystal detectors at near identical times (<12 ns apart) are recorded and used to generate a tomographic image. PET detectors surround the patient and acquire data from all angles simultaneously. Although image quality with PET systems is generally superior to other nuclear medicine-based camera technologies, important photon interactions can cause image degradation and lead to artifacts in the final image that can either create or obscure a lesion. Such artifacts result from photon scatter, attenuation from tissue, random coincidences, dead time, respiratory or body movement, and noise. 22, 23 Of these processes, attenuation of photon activity is probably the factor that most affects image quality. Attenuation is a result of the absorption of either of the pair of emitted photons, resulting in loss of detection of the event source. As the density of tissue changes along the projected pathway of emitted photons, true counts are lost and noise, artifact, and distortion results in a misrepresented image. Without the ability to rectify photon loss through attenuation correction, the activity within various body parts will be misrepresented in the final image. For example, without attenuation correction, the skin shows prominent activity due to a lack of attenuation at the body surface, whereas areas of low attenuation, such as the lungs, show diffusely increased activity (Fig. 21) . Correction of these distortions is important for detailed positional representation, and accurate quantization. Currently, the most common method of measuring count loss uses the use of CT scans built into a PET scanner (PET/CT) to provide accurate attenuation correction. Using PET/CT, attenuation maps are created from the density differences measured by CT. These maps are then used to add counts back to the areas of PET showing high attenuation, such as beneath bone and deep tissues, and to subtract counts in areas with low density, such as the lung tissue 24 (Fig. 21 ). By incorporating attenuation maps from CT, the attenuation-corrected PET (PETAC) images more accurately represent true activity within the body. Owing to the addition or subtraction of counts, however, attenuation correction may result in increased or decreased activity in a location of interest. As a result, a lesion found to be suspicious on CT may not seem metabolically active on PETAC; however, when the nonattenuation-corrected PET (NACPET) images are examined, increased metabolic activity will be seen. For this reason, review of both PETAC and NACPET images can be useful for the interpretation of SPNs. In addition to the accurate and rapid attenuation maps generated by CT, PET/CT offers the advantage of image fusion. Thus, the functional emission data from PET can be combined with the anatomic information on CT to produce a fused image. As a result, a more accurate assessment of a lesion's true malignant character can be performed than using either system alone. 25 
Radioisotopes Used in PET Imaging
The most commonly used radionuclide for thoracic PET is radioactive fluorine ( 18 F) linked to deoxyglucose, resulting in the 2-(fluorine-18) FDG molecule. FDG is a glucose analog with a half-life of 110 minutes that is taken up by almost all tissues in proportion to tissue metabolic activity. FDG allows selective identification of malignant tissues because such tissues overexpress the glucose transport protein, and hexokinase II, and therefore accumulate relatively more radiolabeled tracer than normal tissues. FDG accumulates within metabolically active cells because the radiolabeled glucose analog is phosphorylated by hexokinase II upon entering the cell, forming FDG-6-Phosphate-a negatively charged molecule that becomes trapped within the cell. As tumors grow more rapidly than normal tissue, malignancies will appear as foci of hypermetabolism, or radioactive "hot spots," on FDG PET images. 26 Thoracic FDG PET is most commonly used for lung cancer staging, surveillance for malignancy recurrence, and response to therapy for oncology patients, but has also gained widespread use for the evaluation of the SPN. 2 One limitation of FDG is that it is also taken up in a variety of infectious and inflammatory processes leading to a relatively high but clinically acceptable falsepositive rate. This limitation has resulted in the search for other PET radiopharmaceutical agents that are not taken up by such processes. One such agent is Fluorine-18 3 0 -Deoxy-3 0 -Fluorothymidine. This promising new radiopharmaceutical for ficity for tumor cells through lack of significant accumulation within inflammatory tissues, FDG. 27 Other PET radioisotopes, such as 11 C, 13 N, 15 O are much more difficult to use in routine clinical practice because of their 
Radiation Exposure With PET/CT
Recently, the potential teratogenic and carcinogenic impact of radiation has been the focus of much scientific and journalistic debate. With the advances in radiology technologies, population exposure to radiation has exploded over the last 2 decades. Although controversial, it has been estimated that between 2% to 5% of all cancers in the next 10 to 20 years could arise as a result of medical imaging, 28 and the International Commission on Radiological Protection has estimated that the radiogenic fatal cancer risk for an adult population is approximately 0.005%/mSv. 29 Thus, the American College of Radiology, through its Image Gently program, and other medical societies, have endorsed the concept of weighing the benefits of the test with the potential risks from radiation exposure. 30 The dose of combined PET/CT has been studied using a variety of protocols and systems and ranges anywhere from 3 to 30 mSv per CT scan, depending on the body part and resolution, with the FDG PET contributing approximately 3 to 4 mSv for a typical administered dose of 12 mCi. 29, [31] [32] [33] One study evaluating the radiation exposure of combined PET/CT found that, despite noticeable protocol 
FDG PET Imaging Protocols
Before recommending a PET/CT to a patient, it is important to acquire information regarding diabetes and recent infections because these conditions may alter the uptake of FDG on PET/CT scans and thus affect the results of the imaging study. In addition, it is important to inquire about the patients' physical abilities, such as the ability to lie supine and remain still for approximately 15 to 30 minutes without coughing.
To improve FDG uptake, patients should consume a high fat and protein diet the day before the imaging study is to be performed to reduce myocardial tissue uptake. Patients should also avoid strenuous exercise and alcohol consumption to reduce skeletal muscle uptake. A 4 to 6-hour fast before the administration of FDG is essential to decrease physiological glucose levels and to reduce serum insulin levels to near basal levels. Patients requiring intravenous fluids should avoid using dextrose or parenteral feedings. A fasting glucose level >180 to 200 mg/dL should prompt rescheduling of the examination or injection of short-acting insulin. FDG tumor uptake is reduced in hyperglycemic states and is preferentially driven into skeletal muscles if injected soon after short-acting insulin administration (Fig. 22A) . Therefore, if insulin is administered, FDG injection should be delayed by 4 hours. Patients on a long-acting insulin pumps supplemented with short-acting insulin should withhold the short-acting insulin 4 hours before Imaging Evaluation of the Solitary Pulmonary Nodule FDG injection, but are not required to disconnect their insulin pumps. During injection and uptake phase, the patient should remain seated or recumbent to avoid muscular uptake and remain quiet to reduce laryngeal activity. Typically, a skull base-to-proximal thigh survey is performed to search for abnormal FDG accumulation. Although limited area tumor imaging can be considered, "whole-body" tumor imaging has the advantage of staging the entire body and detecting important "incidental" informationboth anatomic and functional-which, if discovered, could alter patient management (Fig. 23) . The patient should be positioned with the arms elevated over the head if possible. Metallic objects should also be removed from the patient whenever possible due to artifacts. Last, the patient should void before imaging to decrease radiation dose to the renal collecting system and bladder.
Although the timing of the uptake phase is still under scrutiny, most facilities will begin obtaining images no sooner than 60 to 90 minutes after injection. The use of intravenous or oral contrast for PET/CT is not necessary, especially for SPN evaluation, and can occasionally result in an overestimation of a lesion's true metabolic potential or obscure identification of important imaging features, such as calcification within a lesion. However, in certain situations the use of contrast may aid in more accurate lesion evaluation, particularly for complex anatomic locations.
Once the subject is placed in the camera gantry, a lowdose CT scan for attenuation correction with the patient undergoing tidal breathing is obtained. Then, the PET emission scan is acquired. Owing to rapid computer reconstruction times, the technologist can quickly review the PET/CT scan for image quality and can repeat selected bed positions or the entire PET/CT scan in the case of dual time point imaging (DTPI) (Fig. 24) . The studies are typically sent to and archived on PET-specific workstations for quantitative analysis and interpretation. When reviewing PET imaging, it is imperative to have a good understanding of the normal distribution of FDG metabolism, normal variations, and artifacts to avoid misinterpretation. In addition, evaluation of images with and without attenuation correction applied should be reviewed to assess the true activity associated with an SPN (Fig. 21 ).
Factors That Affect Image Quality
Additional factors that can affect image quality with PET/ CT imaging include FDG extravasation into the soft tissues at the injection site ( Fig. 22B ) and motion artifacts, especially respiratory motion (Fig. 25 ). Respiratory motion during acquisition of the images can lead to significant artifacts resulting in lesion obscuration or inaccurate lesion localization. A protocol encouraging tidal breathing should allow the PET and CT images to match closely. Unlike thoracic CT, inspiration to total lung volume should not be used in PET/ CT because it results in respiratory motion misregistration.
A newly developing PET technology is the concept of respiratory-gated PET. Respiratory gating during PET scanning may provide improved lesion detection, more accurate quantification, and improved image quality. Respiratory gating uses a respiratory motion detector to coregister respiratory motion with PET image acquisition and allows more accurate lesion measurement and count density assessment. 35 Respiratory correction methods can be most helpful when assessing SPNs that are close to the diaphragmatic surfaces where motion of the nodule is most pronounced.
Quantification of FDG Activity: Standard Uptake Value
A semiquantitative estimate of tumor biological activity, known as the standard uptake value (SUV), can be derived. The SUV is a commonly accepted measurement of the degree of metabolic activity within tissue. Elevated SUV values indicate robust tracer uptake, whereas a low level indicates little tracer uptake. The activity of the FDG dose, size and location of the lesion, and the injection-to-scan time are all parameters that affect the SUV. As a result, various institutions Typically, the SUV value for discriminating between malignant versus nonmalignant lesions is an SUV>2.5, but this cutoff is arbitrary. Most workstations that display SUVs display values based on the maximum activity in the hottest pixel (SUV max ) or the mean SUV (SUV mean ) for a selected region of interest. The SUV max is the value that typically is reported to the clinician. Errors in measurement using either SUV max or SUV mean can arise due to statistical variation in the count activity of an individual pixel, in the case of SUV max , or partial volume averaging with surrounding normal tissue when using SUV mean . Being consistent in which parameter is used is most important. For qualitative assessment, tracer activity within an SPN is visually compared with background activity in the mediastinum; activity greater than background suggests a metabolically active lesion (Figs. 26, 27 ), whereas lack of tracer accumulation suggests benign etiology (Figs. 28, 29 ). Qualitative assessments by experienced observers provide equally accurate results as quantitative assessments using SUV values. 36 
FDG PET for SPN Evaluation
A number of studies have examined the utility of FDG PET for the evaluation of the SPN. 2 In a study of 61 patients, FDG PET was used to differentiate benign from malignant SPNs with a sensitivity of 93% and a specificity of 88%. 25 In addition, positive and negative predictive values for FDG PET imaging for the detection of malignant SPNs were 95% and 
Limitations of FDG PET/CT for SPN Evaluation
As with any test, false positive and false-negative results occur with FDG PET, and false-positive results are more common than false negative ones. False-positive FDG PET examinations generally occur as a result of metabolically active infections or inflammatory lesions (Figs. 30, 31 ), which show FDG accumulation similar to malignancy. Examples of lesions that may produce false-positive FDG PET results include rheumatoid nodules, granulomas, earlier trauma sites, and reactive lymph nodes. 39 One proposed method to better differentiate benign inflammatory processes from malignant lesions and to decrease the false-positive rate is through DTPI. By imaging a lesion at 2 different time points after a single injection of FDG and measuring the change in SUV between these 2 time points, one can assess the likelihood of malignancy within the lesion. Studies have shown that the uptake of FDG in tumors continues to increase for several hours after initial injection, whereas prolonged uptake of FDG in inflammatory lesions and normal tissue is less common. [40] [41] [42] This is likely related to the low phosphatase activity in cancer cells, and the high glucose uptake through glucose transporter proteins. 43 Preliminary studies have shown a positive change in SUV between 2 time points is characteristic of malignant lung lesions (Fig. 24) . In a study from Matthies et al 41 dual time point scanning using a threshold value of 10% increase between scan 1 and scan 2 reached a sensitivity of 100% with a specificity of 89% for the detection of malignancy. Although promising, DTPI has yet to be validated for routine clinical use.
False-negative results with FDG generally occur in the setting of malignancies with relatively little metabolic activity, such as carcinoid tumors, BACs (Fig. 32) , well differentiated adenocarcinomas of the lung (Fig. 33 ) or malignancies with low viable tumor mass. It has been suggested that FDG PET produces false-negative results in approximately 50% of patients with BAC 38 (Fig. 32 ). In addition, metastasis from certain lesions, such as renal cell carcinoma, testicular cancer, and prostate malignancy, may show little FDG tracer accumulation and may even be undetectable on FDG PET. Another situation associated with false-negative FDG PET results occurs in patients with hyperglycemia. In such patients, FDG competes with circulating glucose, resulting in relatively diminished FDG accumulation within the malignant lesion. Finally, small nodules may not be accurately assessed using FDG PET due to the spatial resolution of PET, which is approximately 7 mm for modern scanners. 44 In fact, few data are available regarding FDG PET performance for nodules <1 cm. 2 In general, negative FDG PET results for nodules <1 cm, and particularly for nodules <7 mm, do not confidently exclude malignancy. 2, 36 
FDG PET for Non-small Cell Lung Carcinoma Assessment
In addition to the role of SUV in planning the evaluation of an SPN, SUVs may also allow assessment of the prognosis of patients with nodules subsequently proven to be malignant. As SUV values allow for quantitative assessment of the metabolic activity within a lesion, they may prove to be a reliable tool for predicting tumor progression, response to therapy, and overall survival in oncology patients. A meta-analysis has shown that patients with malignant lesions showing high SUV values, at all non-small cell lung carcinoma (NSCLCA) stages, have a poorer prognosis than patients with lower SUV values 45 (Fig. 34) . Similarly, patients with stage I NSCLCA who have lower FDG uptake at FDG PET examinations have an improved prognosis 
Integrated PET/CT
Integrated PET/CT scanners fuse images obtained from both PET and CT, allowing for the combined anatomic detail found on thoracic CT with the metabolic localization of PET scans. The combination of anatomic mapping and physiological imaging afforded by integrated PET/CT enhances diagnostic accuracy and provides improved characterization of SPNs as either benign or malignant compared with either modality alone. One study of 42 patients demonstrated that CT and PET alone each correctly characterized 74% of SPNs as benign or malignant, whereas combined PET/CT characterized 93% of SPNs correctly (Fig. 35 ). 47 PET/CT has mostly replaced dedicated PET in current practice and early systems that used CT for attenuation correction and localization of abnormalities have been replaced by diagnostic-quality CT.
PET/CT in Guiding Interventional Procedures
FDG PET/CT may aid in biopsy and treatment planning. In patients with multiple pulmonary nodules or even those with an SPN, the location that has the greatest FDG metabolic activity should be targeted for percutaneous tissue sampling if possible and those areas of little or no FDG metabolism should be avoided. For patients with indeterminate or nondiagnostic tissue sampling results, FDG PET can serve as a "metabolic biopsy." For example, Hain et al 48 evaluated 63 patients with FDG PET who had either undergone unsuccessful biopsy or deferred biopsy because it was considered too dangerous. Using an SUV>2.5 cutoff analysis, positive and negative predictive values were 90% and 85%, respectively. These authors concluded that such a high positive predictive value means that a positive scan must undergo further investigation, whereas lack of FDG uptake allows an indeterminate SPN to be safely followed.
In patients with metabolically active SPNs subsequently proved to be malignant, PET/CT can be used for radiation treatment planning purposes in patients who are not candidates for surgery. 
MANAGEMENT STRATEGIES FOR THE SPN
The primary goals for the management of SPNs are: (1) early detection of malignancy; (2) avoidance of unnecessary intervention/surgery for patients with benign nodules; and (3) efficient and cost-effective use of resources, including minimizing the use of radiation.
Most SPNs in adult patients discovered at chest radiography, if not shown to be stable for more than 2 years and without benign features, should be evaluated with thoracic CT. 44 Thoracic CT is used to characterize the nodule and generate an assessment of the likelihood of malignancy using the morphologic features described previously. In some patients, definitively benign nodule features will be evident at CT, with further management conducted accordingly. In other patients, the nodule will remain indeterminate after thoracic CT, and further evaluation will be required. In such patients, methods that may be used include FDG PET, thoracic CT or MRI using a contrast enhancement protocol, serial CT surveillance to assess for growth over time, biopsy, or resection.
For indeterminate nodules >1 cm, FDG PET is probably the most useful choice for further assessment because FDG PET provides nearly equivalent sensitivity to nodule enhancement using CT for malignancy detection, but with superior specificity. Furthermore, FDG PET provides additional prognostic information for patients subsequently proved to have malignancy. Finally, FDG PET may occasionally disclose other unsuspected sites of disease that may suggest a diagnosis or allow for less invasive intervention than lung biopsy. Negative PET results provide strong, but not definitive, evidence that an SPN is benign. Typically, in the setting of negative FDG PET results, serial thoracic CT is advisable to FIGURE 34 . Positron emission tomography has important implications in predicting prognosis. This patient displays features predictive of inflammatory, aggressive lung cancer. Notice the increased bone marrow uptake (arrowheads, A, B) presumably indicative of high levels of stimulatory cytokines secreted by the carcinoma (arrows, A to C). The higher the standard uptake value the more biologically aggressive the lesion can behave. assess for growth-this approach allows for detection of slow growing malignancies of low metabolic activity ( Figs. 32, 33 ). For nodules <1 cm, serial thoracic CT is probably the most efficacious approach for assessing the malignant potential of a nodule. The interval at which CT should be performed depends on the size of the nodule and the presence or absence of historical factors known to influence the likelihood of malignancy within a pulmonary nodule. A number of approaches to serial surveillance of small nodules have been advocated in the literature, largely in the context of lung cancer screening studies. The approach chosen should be tailored to the patient and the characteristics of the practice location. The Fleischner Society 1 has published recommendations for subcentimeter nodule surveillance using thoracic CT (Table 3) . These recommendations provide an evidence-based approach to small nodule management and may be modified to suit the needs of a particular practice.
In the setting of known malignancy, the presence of small nodules constitutes a dilemma. Unlike patients enrolled in lung cancer screening studies, in which the likelihood of malignancy within a small nodule discovered at thoracic CT is r1%, small nodules in oncology patients may frequently harbor malignancy. 13 In such patients, frequently short interval surveillance CT is used to assess for growth, but the frequency at which thoracic CT should be performed is unclear. Recently, Munden et al 49 showed that 28% of small nodules detected at thoracic CT performed on oncology patients will show growth, suggesting metastatic disease; such growth is usually demonstrable early-at 3 to 6 months. These investigators also found that small nodules stable in size for 1 year are unlikely to represent metastases. 49 As discussed previously, nodules detected at thoracic CT shown to be stable in size or volume for 2 years may be considered benign, with the caveats discussed previously. Ground-glass opacity nodules (part-solid or subsolid nodules) should be followed for a more extended period of time before being dismissed as benign-5 years has been suggested as the appropriate duration of follow-up for such nodules. 2, 14 When a nodule undergoing surveillance CT shows growth, or a lesion undergoing FDG PET shows elevated metabolic activity, absent a clinical correlate (such as recent infection or noninfectious inflammatory conditions known to produce nodular lung disease), a tissue diagnosis is usually warranted. Percutaneous biopsy can be useful in such circumstances. Wallace et al, 50 showed that the diagnostic accuracy for percutaneous biopsy of nodules 8 to 10 mm is nearly as high as that for larger lesions, 50 although the diagnostic yield falls for nodules r7 mm. When nondiagnostic results occur with percutaneous lung biopsy, the nodule should undergo repeat transthoracic biopsy, thoracoscopic biopsy, or serial thoracic CT for growth assessment (Fig. 27) to completely exclude malignancy.
Thoracoscopic biopsy is another option for establishing the diagnosis for small pulmonary nodules. Localization techniques, such as use of hook wires, dye injection, or radionuclide injection, to assist the intraoperative localization of small nodules may be performed.
Finally, for operable patients with SPNs who are at high risk for malignancy, surgery is an appropriate diagnostic and potentially therapeutic option. In such patients, even negative noninvasive evaluations, such as negative FDG PET and CT nodule enhancement studies, cannot lower the probability of malignancy to a low enough level to allow an observational strategy. 44 Similarly, transthoracic biopsy is not recommended in such patients because positive results will not change management and negative results are insufficiently reliable to exclude malignancy. 44 Nevertheless, in practice, FDG PET and a preoperative tissue diagnosis are often obtained in such patients, often to justify to the patient the risks of and need for surgical treatment of an SPN.
CONCLUSIONS
The differential diagnosis of an SPN is broad and management depends on whether the lesion is benign or malignant. The probability of malignancy in an indeterminate SPN discovered at chest radiography in an adult patient is approximately 40%. The goal of imaging studies and minimally invasive procedures is to modify this probability to a high enough level to warrant surgery or to a low enough level to allow observation of the nodule.
Physicians are commonly challenged to balance the benefits of early diagnosis with the potential risks and costs of unnecessary intervention. The optimal balance of diagnostic testing and intervention depends on a number of factors, and no single approach is appropriate for every patient. A number of evidence-based approaches to the evaluation of the SPN zNonsolid (ground-glass) or partly solid nodules may require longer term follow-up to exclude indolent adenocarcinoma. yThe risk of malignancy in this category (<1%) is substantially less than that in a baseline CT scan of an asymptomatic smoker. **History of smoking or other known risk factors. CT indicates computed tomography; PET, positron emission tomography.
